CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes

Blood

Volumn 95, Issue 12, 2000, Pages 3853-3858

  Chu, Peter ^a   Wierda, William G ^a   Kipps, Thomas J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOLOGY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TARGET CELL;

EID: 0034660067     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.12.3853     Document Type: Article

References (43)

1. Kipps TJ. Chronic lymphocytic leukemia and related diseases. In: Beutler E, Lichtman M, Coller B, Kipps TJ, eds. Williams Hematology, 5th ed. New York, McGraw-Hill Inc. 1995;1017-1039.
2. Kalil N, Cheson BD. Chronic lymphocytic leukemia [in process citation]. Oncologist. 1999;4:352-369.
3. Reed JC. Molecular biology of chronic lymphocylic leukemia. Semin Oncol. 1998;25:11-18.
4. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177:925-935.
5. Kato K, Cantwell MJ, Sharma S. Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101:1133-1141.
6. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/ Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol. 1997;97:409-417.
7. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;106:995-1004.
8. Nagata S. Apoptosis by death factor Cell. 1997; 88:355-365.
9. Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia. 1995;9:1227-1232.
10. Younes A, Snell V, Consoli U, et al. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol. 1998;100:135-141.
11. Williams JF, Petrus MJ, Wright JA, et al. Fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous FasL-expressing T cells [in process citation]. Br J Haematol. 1999;107:99-105.
12. de Totero D, Tazzari PL, Quintino S, et al. Modulation of apoptotic programs in chronic lymphocytic leukemia (CLL) cells following CD40/CD40L interaction [abstract]. Blood. 1999;94:309a.
13. Podack ER, Hengartner H, Lichtenheld MG. A central role of perforin in cytolysis? Annu Rev Immunol. 1991;9:129-157.
14. Henkart PA. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity. 1994;1:343-346.
15. Shi L, Kraut RP, Aebersold R, Greenberg AH. A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med. 1992;175:553-566.
16. Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today. 1995;16:202-206
17. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell. 1994;76:977-987.
18. Trapani JA, Sutton VR, Smyth MJ. CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today. 1999;20:351-356.
19. Darmon AJ, Ehrman N, Caputo A, Fujinaga J, Bleackley RC. The cytotoxic T cell proteinase granzyme B does not activate interleukin-1 beta-converting enzyme. J Biol Chem. 1994;269: 32043-32046.
20. Andrade F, Roy S, Nicholson D, et al. Granzyme B directly and efficiently cleaves several down-stream caspase substrates: implications for CTL-induced apoptosis. Immunity. 1998;8:451-460.
21. Sutton VR, Vaux DL, Trapani JA. Bcl-2 prevents apoptosis induced by perform and granzyme B, but not that mediated by whole cytotoxic lymphocytes. J Immunol. 1997;158:5783-5790.
22. Trapani JA, Jans DA, Jans PJ, et al. Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent. J Biol Chem. 1998;273:27934-27938.
23. Romano MF, Lamberti A, Tassone P, et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood. 1998;92:990-995.
24. Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood. 1996;87:2615-2620.
25. Kato K, Santana-Sahagun E, Rassenti LZ, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 1999;104:947-955.
26. Parham P, Barnstable CJ, Bodmer WF. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A, B, C antigens. J Immunol. 1979;123: 342-349.
27. Hu D, Kipps TJ. Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis. Cell Immunol. 1999;195:43-52.
28. Zamzami N, Marchetti P, Castedo M, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med. 1995;181:1661-1672.
29. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777-1783.
30. Kataoka T, Takaku K, Magae J, et al. Acidification is essential for maintaining the structure and function of lytic granules of CTL. Effect of concanamycin A, an inhibitor of vacuolar type H(+)-ATPase, on CTL-mediated cytotoxicity. J Immunol. 1994;153:3938-3947.
31. Kataoka T, Shinohara N, Takayama H, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol. 1996;156:3678-3686.
32. Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria [see comments]. Cell. 1997;91: 627-637.
33. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP [see comments]. Nature. 1997;388:190-195.
34. Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996; 88:41-48.
35. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood. 1997;89:3806-3816.
36. Berke G. The CTL's kiss of death. Cell. 1995;81: 9-12.
37. Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med. 1993;177:195-200.
38. Walsh CM, Glass AA, Chiu V, Clark WR. The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J Immunol. 1994;153:2506-2514.
39. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-3389.
40. Chiu VK, Walsh CM, Liu CC, Reed JC, Clark WR. Bcl-2 blocks degranulation but not fas-based cell-mediated cytotoxicity. J Immunol. 1995;154:2023-2032.
41. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood. 1999;93:1992-2002.
42. Wierda WG, Rassenti LZ, Cantwell MD, Woods SJ, Kipps TJ. A phase I study of CD154 (CD40-ligand) gene therapy for chronic lymphocytic leukemia [abstract]. Blood. 1999;94:602a.
43. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.